NJ jury slaps Roche with $1.5M Accutane verdict; Ex-Actelion execs joins Novimmune as CFO;

@FiercePharma: Novartis and Roche now have France eyeing competition issues. Story | Follow @FiercePharma

@TracyStaton: RT from BioPharmaJosh: WSJ looks at how JNJ beat out NVS & CELG for Imbruvica. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: With hemophilia drugs in the pipeline, Bayer Healthcare will invest €500 M in new production in Germany. Release | Follow @EricPFierce

@CarlyHFierce: From FP Marketing: Hearts, stars, diamonds: Pharma could turn pill shapes into lucky charms. More | Follow @CarlyHFierce

> A New Jersey jury ordered Roche ($RHHBY) to pay $1.5 million in damages to a woman who developed bowel disease after using its Accutane acne medicine. Report

> Novimmune snapped up former Actelion ($ATLN) CFO Andrew J. Oakley to be its new CFO. Report

> Another Indian drug supplier, Canton Laboratories, was slapped with an FDA warning letter for manufacturing shortfalls. Report

> The U.K.'s National Health Service will hike its prescription fees by 40% over the next two years. Report

> Consumer Reports says that acid-reducing drugs like AstraZeneca's ($AZN) Nexium are overused. Report

Medical Device News

@FierceMedDev: Would you wear this first-of-its kind migraine prevention device if it worked? Story | Follow @FierceMedDev

@MarkHFierce: This week's FierceDiagnostics has news on Alzheimer's biomarkers, GE and more. Newsletter | Follow @MarkHFierce

@MichaelGFierce: Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: PowerVision implanted its fluid intraocular lenses into 10 patients as part of a new clinical study. Article | Follow @EmilyWFierce

@GalenMoore: A cash-strapped SF biotech's ovarian cancer drug may actually get to Phase III. Story | Follow @GalenMoore

> Fresenius Medical Care to pour $140M into Tennessee manufacturing expansion. More

> Myriad can't stop Ambry Genetics from selling its breast cancer test--for now. Story

> J&J's $2.5B-plus metal hip settlement offer approaches April 1 deadline. Article

Biotech News

@FierceBiotech: German billionaire pair backs $76M gamble on Glycotope's cancer and fertility drug trials. Article | Follow @FierceBiotech

@JohnCFierce: Purdue preps potential Zohydro killer for FDA review after positive PhIII. News | Follow @JohnCFierce

@DamianFierce: Farewell to dear old Alderley as AstraZeneca finds a buyer for its R&D HQ. Story | Follow @DamianFierce

@EmilyMFierce: FDA approval of Cefaly migraine device is encouraging since triptans used to treat migraines come with risk of rebound headaches. | Follow @EmilyMFierce

> Oxigene roars back to life on positive ovarian cancer study. More

> Geron shares blasted as FDA slams the brakes on imetelstat studies. Piece

Drug Delivery News

> Mallinckrodt's U.S. pain drug approval brings Depomed a $10M delivery tech milestone. More

> NeuroDerm preps for Parkinson's patch PhII trial. Story

> Delivery method uses a cancer cell's power source to trigger drug release. Article

> Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. News

> Caisson expands Novo partnership with $167M insulin-delivery deal. Report

> Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item

Diagnostics News

> 3 Alzheimer's biomarkers build over time but decline after symptoms appear. Story

> Restless legs syndrome mulled as a diagnostic biomarker for multiple conditions. Article

> Boston Heart launches a new inflammation test for cardiovascular disease. Story

> Quest Diagnostics boosts 2014 guidance after closing $570M Solstas acquisition. News

> GE Healthcare prostate cancer imaging agent spurs the formation of a U.K. Dx startup. Story

> Debiopharm invests $6M into Immunexpress for sepsis test development. Brief

Pharma Marketing News

> Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts. Story

> GlaxoSmithKline gets judge's say-so for false-advertising suit against Teva. News

> Can rival allergy-drug launches deliver for both Stallergenes and Merck? Story

> Online coupon bank maps a new marketing route into physicians' offices. Story

> Hearts, stars, diamonds: Pharma could turn pill shapes into Lucky Charms. Article

> German med schools perfectly OK with pharma-rep visits and gifts. Brief

And Finally... The number of young American adults taking ADHD meds nearly doubled from 2008 to 2012. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.